MannKind Q2 Revenue Jumps 43% to $109M, Narrows Loss; Nintedanib DPI Phase 2 Planned
MNKD sits 85% above its 52-week low of $2.23.
Summary
MannKind delivered a strong Q2 with revenue surging 43% year-over-year to $109.4 million, driven by Furoscix and collaboration income, while the GAAP net loss narrowed to $19 million. The Phase 1b INFLO-1 trial of inhaled nintedanib DPI met its safety goal in IPF patients, clearing the way for a global Phase 2 study. Additionally, the ralinepag DPI IND filing remains on track for year-end, with United Therapeutics paying a $5 million milestone. This follows a series of positive regulatory and clinical developments, including FDA approvals for Afrezza pediatric use and Furoscix ReadyFlow, and a recent $50 million private placement. The pipeline progress and revenue growth reinforce the company's turnaround narrative, with analyst consensus strongly bullish at a mean $7.50 target.
At the time of this announcement, MNKD was trading at $4.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $2.23 to $6.51. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.